Marvel Biosciences Corp. has received approval from the TSX Venture Exchange to extend the closing deadline for its private placement from August 31 to September 14, 2026. The company, which develops synthetic chemical derivatives of off-patent drugs targeting neurological and other diseases, keeps all other terms of the offering unchanged. This extension allows Marvel more time to finalize the financing needed to advance its drug redevelopment projects. Investors can expect continued focus on neurological diseases and cancer as Marvel expands its pipeline.
Marvell Technology has delivered a 242% gain over the past year and is expected to continue growing due to accelerating AI infrastructure spending and custom silicon revenue set to more than double in fiscal 2028. The company reported strong Q2 fisca...
Marvell Technology and Broadcom both reported strong AI-driven revenue growth, but at vastly different scales. Broadcom's AI chip revenue hit $16.7 billion, part of its $29.6 billion total, while Marvell's entire business was $2.7 billion. Marvell fo...
Marvell Technology's CEO Matt Murphy attributes the company's 241% stock rise over the past year to a decade-long build of trust with major tech firms. This trust has enabled Marvell to secure significant AI ecosystem partnerships, including deals wi...
Marvell's stock erased most gains following Nvidia CEO Jensen Huang's positive remarks about the company. Finbold's AI analysis predicts a mixed outlook for Marvell, with price targets ranging from a 7.74% drop to a 5.48% rise by September 30, 2026. ...
Broadcom and Marvell recently reported strong AI chip revenues, with Broadcom posting $29.59 billion and Marvell $2.739 billion in their latest quarters. Broadcom's AI semiconductor revenue surged 221% year-over-year, driven by custom XPUs and major ...
